Figure 1.

Clinical manifestations of EAE induced by MOG peptide 35–55. A, C57BL/6 and YFP2.2 mice. B, The effect of GA treatment in C57BL/6 mice treated by five to eight daily injections of GA in different stages of the disease [i.e., starting immediately after disease induction (prevention treatment), starting after the appearance of disease manifestations at day 20 (suppression treatment), or starting during the chronic phase 6 weeks after disease appearance (delayed suppression)]. The injection period of each treatment is illustrated along the x-axis. Six animals were tested in each treatment group.